Veniti's Vici Venous Stent System Introduced With First Cases In Europe

January 23, 2014—Veniti, Inc. (St. Louis, MO) announced the initial commercial-use cases in the European Union for the Veniti Vici venous stent system for the treatment of patients who have symptomatic venous outflow obstruction of the lower extremities. The company announced in November 2013 that it had received European CE Mark approval for the Veniti Vici device, as well as CE Mark approval for the Veniti Veni RF Plus varicose vein ablation system. The Veniti Vici system provides end-to-end crush resistance, high radial resistive force, flexibility, and continuous vein coverage, noted the company.

Stephen Black, MD, a consultant vascular surgeon at St. George’s Vascular Institute, St. George’s Hospital, in London, United Kingdom, implanted Veniti Vici stents in five patients on January 14 and 15.

In the company’s press release, Dr. Black commented, “The Veniti Vici venous stent appears to have the radial strength and vein coverage to provide optimal results in patients with symptomatic outflow obstruction of the lower extremities. Having a stent that was designed from its inception for use in veins makes this an important addition to my treatment options.”

Peter Neglen, MD, who was present at St. Georges during those procedures, added, “The Veniti Vici stent placement today in patients represented the culmination of years of working with venous stent designs to better suit the unique characteristics of the venous anatomy and venous disease.”   

On January 16, Gerard O’Sullivan, MD, of Galway University Hospitals in Galway, Ireland, performed an implantation of the Veniti Vici stent. “The Veniti Vici Venous Stent is a step forward in venous stenting to help treat patients suffering from venous outflow obstruction,” stated Dr. O’Sullivan in the Veniti announcement.

According to the company, more procedures using the Veniti Vici venous stent system are scheduled at various locations in the European Union, including a live case demonstration at the LINC 2014: Leipzig Interventional Course held in Leipzig, Germany, on January 28–31, 2014. The company stated that it will feature the device at the LINC meeting.